| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000023134 |
| Receipt No. | R000026667 |
| Official scientific title of the study | Study on the absorption of sulforaphane |
| Date of disclosure of the study information | 2016/07/19 |
| Last modified on | 2018/09/20 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Study on the absorption of sulforaphane | |
| Title of the study (Brief title) | Study on the absorption of sulforaphane | |
| Region |
|
|
| Condition | |||
| Condition | Healthy adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To reveal that consumption both sulforaphane glucosinolate (SGS) and specific components changes the sulforaphane absorption. |
| Basic objectives2 | Bio-availability |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The amount of sulforaphane metabolite in urine |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 4 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | The subjects intake placebo food that contain SGS (30 mg) and not contain specific components at single. | |
| Interventions/Control_2 | The subjects intake test food that contain SGS (30 mg) and low dose of specific components at single. | |
| Interventions/Control_3 | The subjects intake test food that contain SGS (30 mg) and middle dose of specific components at single. | |
| Interventions/Control_4 | The subjects intake test food that contain SGS (30 mg) and high dose of specific components at single. | |
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Subjects who satisfy the following conditions
1) Who do not fit key exclusion criteria 2) Who provide written informed consents |
|||
| Key exclusion criteria | 1. Who has digestion and absorption disorder.
2. Who has smoking habit. 3. Who take pharmaceutical or dietary supplement routinely. 4. Who has food allergy to the test foods 5. Who will get pregnant or breast-feed during the study period 6. Who join other human studies 7. Who are judged unsuitable for this study by principal investigator |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Satoshi Sunabori |
| Organization | Innovation Division, Kagome Co., Ltd. |
| Division name | Nature and Wellness Research Department |
| Address | 17 Nishitomiyama, Nasushiobara, Tochigi, Japan |
| TEL | +81-0287-36-2935 |
| Satoshi_Sunabori@kagome.co.jp | |
| Public contact | |
| Name of contact person | Yukihiro Nobuta |
| Organization | Innovation Division, Kagome Co., Ltd. |
| Division name | Nature and Wellness Research Department |
| Address | 17 Nishitomiyama, Nasushiobara, Tochigi, Japan |
| TEL | +81-0287-36-2935 |
| Homepage URL | |
| Yukihiro_Nobuta@kagome.co.jp | |
| Sponsor | |
| Institute | Innovation Division, Kagome Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Innovation Division, Kagome Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026667 |